GelStat Corporation (PINK:GSAC) announced the appointment of Mr. Paul W. Bucha to its board of directors.
GelStat Corporation is a consumer healthcare based firm extensively involved in the development and marketing of safe and effective over-the-counter (OTC) products treating pain, inflammation and sleep disorders.
Mr. Bucha completed his Masters of Business Administration at Stanford University Graduate School of Business and achieved his undergraduate education at the United States Military Academy at West Point. He inherits over 40 years of experience, serving in several senior executive level leadership positions in the realm of real estate, international trade, international licensing, manufacturing, marketing hospitality and defense contracting industries. Previously Mr. Bucha served as a Captain and Company Commander in the elite U.S. Army Rangers, and belongs to the 85 living recipients of the Congressional Medal of Honor. While his term of service, he also earned the Bronze Star, a Purple Heart, Vietnam Cross of Gallantry, the Army Commendation Medal, the Civic Action Medal, the National Defense Service Medal, and the Vietnam Service Medal.
Gerald Kieft, CEO of GelStat, has shared his word of thanks with Mr. Bucha for prefering to join their Board of Directors, and is eagerly looking forward to his guidance. He further stated that owing to his extensive experience, his background and skills, the company is convinced about his ability in the further execution of their business plan.
Shares of GSAC ended lower by 14.30% to $0.0300.
The assembled information distributed by headlineotc.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Headlineotc.com does expect that investors will buy and sell securities based on information assembled and presented herein. Headlineotc.com will not be responsible in any way for or accept any liability for any losses arising from an investor’s reliance on or use of information obtained from our website or emails. PLEASE always do your own due diligence, and consult your financial adviser.